Department of Internal Medicine-Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Department of Animal Genetics and Breeding, West Bengal University of Animal and Fishery Sciences, Kolkata, West Bengal, India.
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e1052-e1059. doi: 10.1210/clinem/dgaa769.
Decade-old studies have demonstrated that microbes living in our gut (microbiota) contribute to both maintaining normal metabolic function and to the pathology of metabolic diseases, such as obesity and diabetes. Emerging evidence suggests that gut microbiota influences the personalized effects of diets and drugs and impact the gut-brain axis and leaky gut inflammation to control metabolic function/diseases. Gut microbiota can be an ideal source of prognostic markers and therapies for metabolic diseases. Here we discuss the emerging concepts in the area of microbiota and metabolic interactions in personalized nutrition, drug response, and disease prognosis.
十余年来的研究表明,存在于我们肠道内的微生物(肠道菌群)不仅有助于维持正常的新陈代谢功能,也与肥胖和糖尿病等代谢疾病的病理变化有关。新出现的证据表明,肠道菌群会影响饮食和药物的个体效果,并影响肠道-大脑轴和肠道渗漏性炎症,以控制代谢功能/疾病。肠道菌群可以成为代谢疾病预后标志物和疗法的理想来源。在此,我们讨论了在个性化营养、药物反应和疾病预后中,有关微生物组和代谢相互作用的新兴概念。